Global Regulators Increase CAR T Scrutiny in Wake of FDA’s Investigation

Regulatory authorities worldwide are tightening their monitoring mechanisms and launching their own investigations after reports of secondary malignancies potentially linked to chimeric antigen receptor T cell therapies.